Overview of Taris GemRIS, a Novel Drug Delivery System for Bladder Cancer.

Loading...
Thumbnail Image

Date

2019-09-24

Journal Title

Journal ISSN

Volume Title

Repository Usage Stats

69
views
1245
downloads

Citation Stats

Abstract

GemRIS, an implantable drug delivery system from Taris Biomedical that delivers continuous intravesical gemcitabine, shows potential for use in multiple bladder cancer settings. Ongoing and recently completed phase 1 trials in non-muscle-invasive as well as muscle-invasive bladder cancer are yielding promising preliminary results.

Department

Description

Provenance

Subjects

Citation

Published Version (Please cite this version)

10.1016/j.euf.2019.09.006

Publication Info

Grimberg, Dominic C, Ankeet Shah and Brant A Inman (2019). Overview of Taris GemRIS, a Novel Drug Delivery System for Bladder Cancer. European urology focus. 10.1016/j.euf.2019.09.006 Retrieved from https://hdl.handle.net/10161/20748.

This is constructed from limited available data and may be imprecise. To cite this article, please review & use the official citation provided by the journal.

Scholars@Duke

Shah

Ankeet Shah

Assistant Professor of Urology

Unless otherwise indicated, scholarly articles published by Duke faculty members are made available here with a CC-BY-NC (Creative Commons Attribution Non-Commercial) license, as enabled by the Duke Open Access Policy. If you wish to use the materials in ways not already permitted under CC-BY-NC, please consult the copyright owner. Other materials are made available here through the author’s grant of a non-exclusive license to make their work openly accessible.